Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease

William Kielbasa; Paul Goldsmith; Kevin B. Donnelly; Hugh Nuthall; Sergey Shcherbinin; Adam Fleisher; J. Hendle; Susan L. DuBois; Stephen L. Lowe; Feiyu Fred Zhang; Eric M. Woerly; Nicolas Dreyfus; David Evans; Jeremy Gilmore; Michele Mancini; Cristian C. Constantinescu; Roger N. Gunn; David Russell; Emily C. Collins; Mirosław Bryś; Michael Hutton; Dustin J. Mergott

doi:10.1002/trc2.70020

Abstract

This is the authors' abstract. We don't add key points for this paper.

Ceperognastat is a highly potent, CNS-penetrant OGA inhibitor.Ceperognastat is both orally available and CNS-penetrant even when given at low doses.Ceperognastat can achieve > 95% OGA enzyme occupancy in the animal and human brain.Ceperognastat had an acceptable safety profile in Phase 1 clinical studies.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kielbasa et al. (2024) studied this question.

synapsesocial.com/papers/69da718ca6045d71bfa3cbee https://doi.org/10.1002/trc2.70020

View Full Paper

Ask AI

Bookmark

Share

Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease

Abstract

Ask about this paper

Discussion

Cite This Study

Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading